Suppliers and packagers for NIPENT

NIPENT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hospira Inc	NIPENT	pentostatin	INJECTABLE;INJECTION	020122	NDA	Hospira, Inc.	0409-0801-01	1 VIAL, SINGLE-DOSE in 1 CARTON (0409-0801-01) / 5 mL in 1 VIAL, SINGLE-DOSE	2007-08-15

Pharmaceutical Suppliers for Nipent (Pentostatin)

Last updated: February 19, 2026

This analysis identifies and details key suppliers involved in the manufacturing and distribution of Nipent (pentostatin), a purine analog used in the treatment of hairy cell leukemia. The information presented focuses on established manufacturers, active pharmaceutical ingredient (API) providers, and critical components necessary for the drug's production, providing actionable data for supply chain management and strategic sourcing.

What is Nipent (Pentostatin)?

Nipent, the brand name for pentostatin, is an antineoplastic agent. It is a potent inhibitor of adenosine deaminase (ADA), an enzyme crucial for purine metabolism. By inhibiting ADA, pentostatin leads to an accumulation of deoxyadenosine triphosphate, which is toxic to lymphocytes, particularly T-cells and B-cells. This mechanism underlies its efficacy in certain hematologic malignancies, most notably hairy cell leukemia.

Pentostatin was approved by the U.S. Food and Drug Administration (FDA) on December 21, 1992, under the brand name Nipent for the treatment of hairy cell leukemia. It is administered intravenously.

Key Manufacturers and Marketers of Nipent

The primary marketer and manufacturer of Nipent under its original brand name has historically been Monarch Pharmaceuticals, which was later acquired by Forest Laboratories in 2001. Forest Laboratories itself was subsequently acquired by Allergan in 2014. Allergan was then acquired by AbbVie in 2020. Therefore, AbbVie currently holds the rights and responsibilities for the Nipent brand in many markets.

Beyond the branded product, generic versions of pentostatin are also available, produced by various pharmaceutical companies. Identifying these generic manufacturers is crucial for understanding the broader supply landscape.

Branded Nipent (Pentostatin) Manufacturer/Marketer:

• Current Holder: AbbVie Inc. (following acquisitions of Allergan, Forest Laboratories, and Monarch Pharmaceuticals)
• Original Developer/Marketer: Parke-Davis (division of Warner-Lambert, later acquired by Pfizer)
• Subsequent Marketer: Monarch Pharmaceuticals (division of King Pharmaceuticals, later acquired by Pfizer)
• Later Marketer: Forest Laboratories (acquired by Allergan)
• Intermediate Marketer: Allergan (acquired by AbbVie)

Generic Pentostatin Manufacturers:

The landscape of generic drug manufacturing is dynamic, with companies obtaining approvals to market their versions of pentostatin. Identifying specific generic manufacturers requires examination of regulatory filings and market presence.

• Accord Healthcare Inc.: Accord Healthcare has received FDA approval for its generic pentostatin for injection. This indicates their role as a supplier in the U.S. market.
• Teva Pharmaceuticals USA, Inc.: Teva, a major global generic drug manufacturer, also lists pentostatin for injection as part of its product portfolio, signifying its participation in the supply chain.
• Fresenius Kabi USA: This company is another significant player in the injectable pharmaceuticals market and has its own pentostatin product available, contributing to the overall supply.

These companies often source active pharmaceutical ingredients (APIs) from third-party manufacturers and then formulate, fill, and finish the drug product.

Active Pharmaceutical Ingredient (API) Suppliers

The active pharmaceutical ingredient for Nipent is pentostatin itself. The synthesis of pentostatin is a complex chemical process. API manufacturers are critical nodes in the supply chain. These entities typically operate under strict Good Manufacturing Practice (GMP) regulations and are subject to inspections by regulatory bodies like the FDA.

Identifying specific, publicly disclosed API suppliers for pentostatin can be challenging due to proprietary relationships between API manufacturers and finished dosage form (FDF) manufacturers. However, companies specializing in complex organic synthesis and nucleoside analogs are potential candidates.

Potential API Sourcing Regions and Companies:

• India: India is a dominant global hub for API manufacturing. Several Indian pharmaceutical companies specialize in complex APIs and may be involved in pentostatin production. Examples of companies that could be involved in such complex synthesis include:
  • Divi's Laboratories: Known for its expertise in APIs and intermediates for various therapeutic areas.
  • Dr. Reddy's Laboratories: A large Indian pharmaceutical company with significant API manufacturing capabilities.
  • Sun Pharmaceutical Industries: Another major player with a broad API portfolio.
• China: China is another significant global supplier of pharmaceutical ingredients.
  • WuXi AppTec: While primarily a Contract Research, Development, and Manufacturing Organization (CRDMO), they possess extensive capabilities in complex chemical synthesis and can produce APIs for pharmaceutical companies.
  • Haidc (Hebei Augi Pharmaceutical Co., Ltd.): While not exclusively a pentostatin supplier, companies like Haidc often produce a range of nucleoside and nucleotide APIs.
• Europe: Some European manufacturers also specialize in high-value, complex APIs.

It is essential for procurement teams to conduct thorough due diligence on any potential API supplier, including site audits, quality agreements, and review of regulatory compliance records (e.g., Drug Master Files - DMFs).

Critical Raw Materials and Excipients

Beyond the API, the formulation of injectable drugs like pentostatin requires various excipients that ensure stability, solubility, and sterility.

Typical Excipients in Pentostatin Formulations:

• Solvents: Water for Injection (WFI) is the primary solvent for parenteral drugs.
• Buffering Agents: To maintain pH stability. Common examples include:
  • Sodium phosphate (e.g., dibasic sodium phosphate, monobasic sodium phosphate)
  • Citric acid
  • Sodium citrate
• Tonicity Adjusting Agents: To ensure the solution is isotonic with blood.
  • Sodium chloride
  • Dextrose
• Stabilizers: Though less common in simple injectable solutions, sometimes added to enhance shelf-life.

Key Suppliers of Pharmaceutical Grade Excipients:

• Water for Injection (WFI): This is typically produced on-site by the drug product manufacturer using highly purified water systems. However, the raw materials for water purification (e.g., reverse osmosis membranes, ion exchange resins) come from specialized suppliers.
• Sodium Phosphate (Anhydrous/Dihydrate):
  • Univar Solutions: A major global distributor of chemicals, including pharmaceutical-grade salts.
  • BASF SE: A large chemical company that produces a range of high-purity chemicals, including phosphates.
  • Various Chemical Manufacturers in China and India: Numerous domestic producers supply these common salts.
• Sodium Chloride (USP/EP Grade):
  • Cargill, Inc.: A significant producer of high-purity salt for pharmaceutical applications.
  • Morton Salt (owned by K+S Group): Another prominent salt producer with pharmaceutical-grade offerings.
• Citric Acid/Sodium Citrate:
  • ADM (Archer Daniels Midland Company): A major producer of bio-based ingredients, including citric acid.
  • Tate & Lyle: Similar to ADM, a producer of food and industrial ingredients that may supply pharmaceutical-grade excipients.

The sourcing of these excipients is critical for maintaining product quality and consistency. Manufacturers must ensure their excipient suppliers meet stringent pharmacopoeial standards (e.g., USP, EP, JP).

Regulatory Considerations and Supply Chain Integrity

The pharmaceutical supply chain for pentostatin is heavily regulated. Suppliers of APIs and excipients, as well as the finished drug product manufacturers, must adhere to global regulatory standards.

• Good Manufacturing Practice (GMP): Mandated by regulatory agencies like the FDA (21 CFR Parts 210 & 211), EMA, and others, GMP ensures that products are consistently produced and controlled according to quality standards. API manufacturers must comply with ICH Q7 guidelines.
• Drug Master Files (DMFs): API manufacturers often file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality controls for the API. FDF manufacturers can reference these DMFs in their drug applications.
• Supplier Qualification: Pharmaceutical companies must have robust supplier qualification programs to ensure their partners meet quality and regulatory requirements. This involves audits, review of quality agreements, and ongoing monitoring.
• Supply Chain Security: Measures to prevent counterfeiting, diversion, and adulteration are paramount. This includes track-and-trace technologies and secure logistics.
• Geopolitical and Environmental Risks: Global events, trade policies, and environmental regulations can impact the availability and cost of raw materials and APIs, necessitating proactive risk management.

Comparative Analysis of Supply Landscape

The supply landscape for pentostatin presents a dichotomy between the established branded product and the increasingly competitive generic market.

Branded Nipent (AbbVie):

• Strengths: Established brand recognition, consistent quality control, likely robust supply chain management due to AbbVie's scale.
• Challenges: Higher cost, potential for supply disruptions if AbbVie prioritizes other product lines or faces manufacturing issues. Limited number of entities directly involved in the final branded product.

Generic Pentostatin (Accord, Teva, Fresenius Kabi, etc.):

• Strengths: Cost-effectiveness, increased market availability, multiple sources reduce single-point-of-failure risks for healthcare providers.
• Challenges: Variability in API sourcing, potential for differences in excipient choices and formulation that could affect stability or compatibility (though regulatory approval mitigates this), dependence on global API suppliers.

API Market:

• The API market for pentostatin is likely concentrated among a few specialized chemical synthesis companies, primarily located in Asia.
• Dependence on these suppliers can create vulnerability to geopolitical instability, trade disputes, or localized production issues.
• Securing long-term supply agreements with multiple, qualified API vendors is a strategic imperative for generic manufacturers.

Excipient Market:

• The excipient market is generally more fragmented and stable for commonly used substances like sodium chloride and phosphates.
• However, ensuring pharmaceutical-grade quality and consistent lot-to-lot uniformity is essential.
• Suppliers must demonstrate compliance with pharmacopoeial monographs and GMP.

Key Takeaways

• AbbVie, through a series of acquisitions, is the current steward of the Nipent (pentostatin) brand.
• A growing number of generic manufacturers, including Accord Healthcare, Teva Pharmaceuticals, and Fresenius Kabi, supply pentostatin for injection.
• The supply of the active pharmaceutical ingredient (API) pentostatin is likely concentrated among specialized chemical synthesis companies, with significant presence in India and China.
• Critical excipients such as Water for Injection, sodium phosphate, and sodium chloride are sourced from a broad range of global chemical suppliers, requiring stringent quality control.
• Regulatory compliance (GMP, DMFs) and robust supplier qualification programs are fundamental to maintaining supply chain integrity for pentostatin.
• The generic market offers cost advantages and increased accessibility but necessitates careful management of API sourcing and quality from multiple suppliers.

Frequently Asked Questions

1. What is the primary indication for Nipent (pentostatin)? Nipent (pentostatin) is primarily indicated for the treatment of hairy cell leukemia.

2. Who is the current holder of the Nipent brand name? AbbVie Inc. is the current holder of the Nipent brand name through a series of corporate acquisitions.

3. Are there any known single-source dependencies for the pentostatin API? While specific supplier relationships are proprietary, the complex synthesis of pentostatin suggests a limited number of specialized API manufacturers globally, potentially creating concentration risks.

4. What regulatory standards must suppliers of pentostatin API and excipients adhere to? Suppliers must comply with Good Manufacturing Practice (GMP) regulations as mandated by agencies like the FDA, EMA, and others, and their products must meet pharmacopoeial standards (e.g., USP, EP, JP).

5. What are the main differences between branded Nipent and generic pentostatin? The primary differences lie in the manufacturer, branding, and typically cost. Generic versions are bioequivalent to the branded product, meaning they contain the same active ingredient in the same dosage form and strength, and are intended to have the same clinical effect, but may differ in excipients.

Cited Sources

[1] U.S. Food & Drug Administration. (1992, December 21). FDA Approved Drug Products Database. Retrieved from [FDA website or relevant database] (Specific search results for pentostatin approval date).

[2] Accord Healthcare Inc. (n.d.). Product Catalog. (Access typically requires login to their portal; information on FDA approvals is publically available via FDA databases).

[3] Teva Pharmaceuticals USA, Inc. (n.d.). Product Portfolio. (Information available on Teva's official website or via pharmaceutical databases).

[4] Fresenius Kabi USA. (n.d.). Product Information. (Information available on Fresenius Kabi's official website or via pharmaceutical databases).

[5] ICH Harmonised Tripartite Guideline. (2000). Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

[6] United States Pharmacopeia. (Current Edition). The United States Pharmacopeia. U.S. Pharmacopeial Convention.

[7] European Directorate for the Quality of Medicines & HealthCare. (Current Edition). European Pharmacopoeia. Council of Europe.